STOCKHOLM, SWEDEN (UroToday.com) - Infection with human papillomavirus (HPV) is a known risk factor for penile cancer (PC) development.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The reported proportion of PC associated with high-risk HPV ranges from 30% to 100%. Given the rising incidence of HPV-associated head and neck squamous cell cancer, Dr. Djajadiningrat and colleagues sought to assess the prevalence of high-risk HPV in a contemporary cohort of patients with PC. PC specimens from 213 patients, treated between 2001 and 2009, were tested for high-risk HPV DNA using PCR. Positive samples were then typed using a reverse line blot assay. Survival rates were calculated and compared based on the presence of high-risk PC.
Fifty-three men (25%) had high-risk HPV DNA detected in their specimen, with a predominance of subtype 16 (79%). At a median follow-up of 59 months (range 40-68 months), 5-year cancer-specific survival was 82% and 96% in patients with high-risk HPV-negative and positive disease, respectively. As has been previously described, HPV infection is present in a small subset of PC patients, and the prevalence of HPV-associated PC has not increased over the past decade. Further, infection with high-risk HPV (as evidenced by the presence of high-risk HPV DNA) appears to confer a survival advantage for patients with PC.
Presented by R.S. Djajadiningrat at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden
The Netherlands Cancer Institute, Department. of Urology, Amsterdam, Netherlands
Written by Jeffrey J. Tomaszewski, MD, medical writer for UroToday.com